Susanne Johansson

Publications
Public outreach and news

Articles

Article: EUROPEAN UROLOGY ONCOLOGY. 2025;:S2588-9311(25)00037-9
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.
Crippa A; Laere BD; Discacciati A; Larsson B; Persson M; Johansson S; D'hondt S; Hjälm-Eriksson M; Pettersson L; Enblad G; Ullén A; Lumen N; Karlsson CT; Sandzén J; Jänes E; Ghysel C; Olsson M; Sautois B; Schatteman P; Roock WD; Bruwaene SV; Verbiene I; Darras J; Everaert E; Maeseneer DD; Anden M; Strijbos M; Luyten D; Mortezavi A; Oldenburg J; Ost P; Lindberg J; Grönberg H; Eklund M; ProBio Investigators
Article: NATURE MEDICINE. 2024;30(11):3291-3302
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
De Laere B; Crippa A; Discacciati A; Larsson B; Persson M; Johansson S; D'hondt S; Bergstrom R; Chellappa V; Mayrhofer M; Banijamali M; Kotsalaynen A; Schelstraete C; Vanwelkenhuyzen JP; Hjalm-Eriksson M; Pettersson L; Ullen A; Lumen N; Enblad G; Thellenberg Karlsson C; Janes E; Sandzen J; Schatteman P; Vigmostad M; Olsson M; Ghysel C; Sautois B; De Roock W; Van Bruwaene S; Anden M; Verbiene I; De Maeseneer D; Everaert E; Darras J; Aksnessether BY; Luyten D; Strijbos M; Mortezavi A; Oldenburg J; Ost P; Eklund M; Gronberg H; Lindberg J

All other publications

Corrigendum: NATURE MEDICINE. 2024;30(11):3381
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial (vol 30, pg 3291, 2024)
De Laere B; Crippa A; Discacciati A; Larsson B; Persson M; Johansson S; D'hondt S; Bergstrom R; Chellappa V; Mayrhofer M; Banijamali M; Kotsalaynen A; Schelstraete C; Vanwelkenhuyzen JP; Hjaelm-Eriksson M; Pettersson L; Ullen A; Lumen N; Enblad G; Karlsson CT; Jaenes E; Sandzen J; Schatteman P; Vigmostad MN; Olsson M; Ghysel C; Sautois B; De Roock W; Van Bruwaene S; Anden M; Verbiene I; De Maeseneer D; Everaert E; Darras J; Aksnessether BY; Luyten D; Strijbos M; Mortezavi A; Oldenburg J; Ost P; Eklund M; Gronberg H; Lindberg J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:647-648
Real world experience of fingolimod after switching multiple sclerosis (MS) therapy; focus on natalizumab naive and experienced persons with MS, respectively
Forsberg L; Johansson S; Frisell T; Hillert J; Nilsson P; Dahle C; Sveningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:336-337
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1)
Johansson S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:285-286
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab
Johansson S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:284-285
The IMSE 2 study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod
Johansson S; Forsberg L; Nordin N; Hillert J; Svenningsson A; Lycke J; Burman J; Landtblom A-M; Walentin F; Martin C; Nilsson P; Dahle C; Piehl F; Olsson T

Articles

All other publications

News from KI

Events from KI